Anebulo Pharmaceuticals, Inc.

NASDAQ•ANEB

CEO: Dr. Joseph F. Lawler M.D., Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2021-05-07

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

联系方式

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, 78734, United States

512-598-0931

www.anebulo.com

市值

$16.31M

市盈率 (TTM)

-2.1

17.8

股息率

52周最高

$3.42

52周最低

$0.30

52周范围

排名56Top 81.7%

2.5

F-Score

改良版 Piotroski 分析

基于 6 年期基本面

疲弱 • 2.5 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2020-2025

财务仪表盘

Q2 2026 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.05+0.00%

近4季度走势

自由现金流

-$1.31M+0.00%

近4季度走势

2026 Q2 财报亮点

核心亮点

Six Month Net Loss Reduced Six month net loss decreased to $(4.158M) USD, reflecting $506K improvement against prior period results.

R&D Spending Decreased Six month R&D expenses fell $561K USD to $1.975M, due to lower contract manufacturing activities.

Cash Position Maintained Cash and equivalents stood at $9.042M USD as of December 31, 2025, following operating cash usage.

Financing Provided Cash Inflow Financing activities provided $15.0M USD cash inflow, supporting operations before the reporting period end date.

关注风险

Future Funding Dependency Expect continued operating losses; cash runway estimated for 12 months requiring future capital raises.

Clinical Trial Uncertainty Success hinges on favorable clinical trial results and obtaining necessary regulatory approvals for product candidates.

Going Private Liquidity Risk Plan to delist from Nasdaq; reduced public information availability may increase stock illiquidity and volatility.

Equity Dilution Risk Future equity financing or Loan Agreement stock issuance will cause substantial dilution to existing common stockholders.

前瞻展望

Prioritizing Pediatric IV Formulation Prioritizing intravenous formulation development for pediatric indication, seeking faster regulatory pathway for emergency treatment.

IV Study Currently Ongoing Initiated ongoing single ascending dose study for IV selonabant in healthy adults during third quarter 2025.

Government Operations Disruption Risk Future government shutdowns pose risk to timely regulatory reviews, grant disbursements, and clinical trial oversight.

G&A Expenses Expected Decline General administrative expenses expected to decrease following completion of planned deregistration from SEC reporting.

同行对比

营业收入 (TTM)

MGNX

$126.00M

-10.8%

ZNTL

$26.87M

-33.8%

SRZN

$3.60M

-64.0%

毛利率 (最新季度)

SRZN

100.0%

+0.0pp

MGNX

81.6%

+19.9pp

ANEB

0.0%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
SRZN	$245.06M	-2.8	-4404.2%	7.5%
ZNTL	$157.87M	-1.1	-51.5%	11.2%
MGNX	$135.37M	-1.8	-98.3%	13.7%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月11日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据